Coherus Oncology (CHRS) Cash from Investing Activities (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Cash from Investing Activities data on file, last reported at $30.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 275.31% year-over-year to $30.7 million; the trailing twelve-month figure through Mar 2026 stood at $423.2 million (up 4102.03% YoY), and the FY2025 full-year result was $375.1 million, up 62.85% from the prior year.
• Cash from Investing Activities advanced to $30.7 million in Q1 2026, from -$2.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $462.6 million in Q2 2025 to a low of -$129.9 million in Q4 2022.
• A 5-year average of $36.1 million and a median of $444000.0 in 2024 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities surged 11160.39% in 2023 and sank 15241.22% in 2025, its largest moves.
• Tracing CHRS's Cash from Investing Activities over 5 years: stood at -$129.9 million in 2022, then jumped by 127.1% to $35.2 million in 2023, then slumped by 101.54% to -$542000.0 in 2024, then slumped by 423.62% to -$2.8 million in 2025, then surged by 1180.16% to $30.7 million in 2026.
• Business Quant data shows CHRS's Cash from Investing Activities at $30.7 million in Q1 2026, -$2.8 million in Q4 2025, and -$67.2 million in Q3 2025.